MDL® Isentris® 2.0 Offers Significant R&D Advantage

50% of Elsevier MDL's top pharmaceutical and chemical customers have licensed Isentris

San Ramon, CA - January 10, 2007 - Elsevier MDL has unveiled a significant upgrade to the MDL® Isentris® system for integrating information and software applications into scientists' workflows. MDL Isentris 2.0 features hundreds of new capabilities and demonstrable and meaningful performance improvements that give pharmaceutical, biotech and life sciences organizations unequaled ability to improve R&D productivity through better data management, lowered cost of ownership, faster workflow processes and easier information access and reporting.

"MDL Isentris 2.0 offers features, performance and potential well beyond MDL® ISIS, the industry standard for the past 15 years," said Lars Barfod, President and CEO of Elsevier MDL.

"Unique new features such as a visual reaction planner offer scientists better day-to-day workflow support. Dramatic performance improvements strengthen the value of Isentris from small to global multi-site R&D labs. And standardized development tools make it easy for organizations to customize systems to meet their needs. More and more of our major customers are migrating to Isentris to capitalize on these advantages."

MDL software is used at virtually every major pharmaceutical company, and at biotechnology, chemical and research institutions around the world. Following recent evaluations of Isentris 2.0, several more leading companies have purchased the new-generation system, bringing the number of top 30 Elsevier MDL customers that have adopted Isentris to 15.

Dr. Dominique Swinnen, a Senior Scientist at Serono who viewed a prerelease, commented: "Isentris 2.0 looks very promising. I was really impressed with how user-friendly it was and especially with the reaction planning functionality. The ability to explore precursor reaction steps and quickly build reaction plans looks very useful and could save us a lot of time during our synthesis preparation."

The Isentris 2.0 release features proven performance on databases of over 5 million reactions and 20 million structures. Reaction fast search gives substantial performance improvements over previous cartridge-based search engines, up to 100 times faster in some cases. Isentris now offers up to 15 times faster browsing over wide area networks than ISIS, and allows scientists to load scientific data into Microsoft Excel as much as six times faster, and copy, paste and sort the data twice as fast. Isentris can support hundreds of simultaneous users on a single mid-sized server.

I Isentris lets scientists search multiple databases with a single query, save and reuse sophisticated searches and create personal data views without IT assistance. Scientists can find information faster, explore structure-activity relationships, collaborate, pursue hypotheses and gain insight for informed, intelligent decisions.

For organizations, Isentris is designed to handle the massive loads, diverse data types and pressure of global R&D networks, while offering higher ROI and lower IT costs. Pre-built development components in Isentris enable IT groups to rapidly create custom scientific applications using Microsoft .NET technology. IT groups can reduce support workloads by providing scientists with self-service data access and consistent, easy to learn applications. And integrated access to internal proprietary and commercial data sources offers significant workflow and efficiencies.

For more information visit A whitepaper is available on request.


About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful scientific R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media Contact:
Jean Holt
Sr. Director, Marketing & Communications
Phone: +1 925 543-5400